For example, the triple negative molecular subtype (estrogen/progesterone/HER2 negative) accounts for approximately 40% of breast cancer LMD cases, however only is diagnosed in 10% of all breast cancer patients, indicating a clear overrepresentation of this subtype among LMD patients. Here, ERBB2 is linked to breast carcinoma.